These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Enrichment of Prevotella intermedia in human colorectal cancer and its additive effects with Fusobacterium nucleatum on the malignant transformation of colorectal adenomas. Lo CH; Wu DC; Jao SW; Wu CC; Lin CY; Chuang CH; Lin YB; Chen CH; Chen YT; Chen JH; Hsiao KH; Chen YJ; Chen YT; Wang JY; Li LH J Biomed Sci; 2022 Oct; 29(1):88. PubMed ID: 36303164 [TBL] [Abstract][Full Text] [Related]
24. Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients. Kunzmann AT; Proença MA; Jordao HW; Jiraskova K; Schneiderova M; Levy M; Liska V; Buchler T; Vodickova L; Vymetalkova V; Silva AE; Vodicka P; Hughes DJ Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1891-1899. PubMed ID: 31367996 [TBL] [Abstract][Full Text] [Related]
25. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. Guo P; Tian Z; Kong X; Yang L; Shan X; Dong B; Ding X; Jing X; Jiang C; Jiang N; Yu Y J Exp Clin Cancer Res; 2020 Sep; 39(1):202. PubMed ID: 32993749 [TBL] [Abstract][Full Text] [Related]
26. Detection of Fusobacterium nucleatum DNA in primary care patient stool samples does not predict progression of colorectal neoplasia. Aitchison A; Pearson JF; Purcell RV; Frizelle FA; Keenan JI PLoS One; 2022; 17(6):e0269541. PubMed ID: 35658028 [TBL] [Abstract][Full Text] [Related]
27. Association Between Fusobacterium nucleatum, Pathway Mutation, and Patient Prognosis in Colorectal Cancer. Lee DW; Han SW; Kang JK; Bae JM; Kim HP; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY Ann Surg Oncol; 2018 Oct; 25(11):3389-3395. PubMed ID: 30062471 [TBL] [Abstract][Full Text] [Related]
28. Relationship between Proença MA; Biselli JM; Succi M; Severino FE; Berardinelli GN; Caetano A; Reis RM; Hughes DJ; Silva AE World J Gastroenterol; 2018 Dec; 24(47):5351-5365. PubMed ID: 30598580 [TBL] [Abstract][Full Text] [Related]
29. Hussan H; Clinton SK; Roberts K; Bailey MT World J Gastroenterol; 2017 Dec; 23(48):8626-8650. PubMed ID: 29358871 [TBL] [Abstract][Full Text] [Related]
30. Ye X; Wang R; Bhattacharya R; Boulbes DR; Fan F; Xia L; Adoni H; Ajami NJ; Wong MC; Smith DP; Petrosino JF; Venable S; Qiao W; Baladandayuthapani V; Maru D; Ellis LM Cancer Prev Res (Phila); 2017 Jul; 10(7):398-409. PubMed ID: 28483840 [TBL] [Abstract][Full Text] [Related]
31. Xu C; Fan L; Lin Y; Shen W; Qi Y; Zhang Y; Chen Z; Wang L; Long Y; Hou T; Si J; Chen S Gut Microbes; 2021; 13(1):1980347. PubMed ID: 34632963 [TBL] [Abstract][Full Text] [Related]
33. The Role of Fecal Liu K; Yang X; Zeng M; Yuan Y; Sun J; He P; Sun J; Xie Q; Chang X; Zhang S; Chen X; Cai L; Xie Y; Jiao X Dis Markers; 2021; 2021():1171239. PubMed ID: 34853619 [TBL] [Abstract][Full Text] [Related]
34. Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population. Suehiro Y; Sakai K; Nishioka M; Hashimoto S; Takami T; Higaki S; Shindo Y; Hazama S; Oka M; Nagano H; Sakaida I; Yamasaki T Ann Clin Biochem; 2017 Jan; 54(1):86-91. PubMed ID: 27126270 [TBL] [Abstract][Full Text] [Related]
35. Microbial dynamics with CRC progression: a study of the mucosal microbiota at multiple sites in cancers, adenomatous polyps, and healthy controls. Senthakumaran T; Moen AEF; Tannæs TM; Endres A; Brackmann SA; Rounge TB; Bemanian V; Tunsjø HS Eur J Clin Microbiol Infect Dis; 2023 Mar; 42(3):305-322. PubMed ID: 36703031 [TBL] [Abstract][Full Text] [Related]
36. Alteration of microRNA-4474/4717 expression and CREB-binding protein in human colorectal cancer tissues infected with Fusobacterium nucleatum. Feng YY; Zeng DZ; Tong YN; Lu XX; Dun GD; Tang B; Zhang ZJ; Ye XL; Li Q; Xie JP; Mao XH PLoS One; 2019; 14(4):e0215088. PubMed ID: 30951563 [TBL] [Abstract][Full Text] [Related]
37. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Jiang SS; Xie YL; Xiao XY; Kang ZR; Lin XL; Zhang L; Li CS; Qian Y; Xu PP; Leng XX; Wang LW; Tu SP; Zhong M; Zhao G; Chen JX; Wang Z; Liu Q; Hong J; Chen HY; Chen YX; Fang JY Cell Host Microbe; 2023 May; 31(5):781-797.e9. PubMed ID: 37130518 [TBL] [Abstract][Full Text] [Related]
38. Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15. Zhu H; Li M; Bi D; Yang H; Gao Y; Song F; Zheng J; Xie R; Zhang Y; Liu H; Yan X; Kong C; Zhu Y; Xu Q; Wei Q; Qin H Nat Commun; 2024 Feb; 15(1):1688. PubMed ID: 38402201 [TBL] [Abstract][Full Text] [Related]
39. Both endogenous and exogenous miR-139-5p inhibit Fusobacterium nucleatum-related colorectal cancer development. Zhao Y; Tao Q; Li S; Zheng P; Liu J; Liang X Eur J Pharmacol; 2020 Dec; 888():173459. PubMed ID: 32768506 [TBL] [Abstract][Full Text] [Related]
40. Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models. Dong J; Li Y; Xiao H; Zhang S; Wang B; Wang H; Li Y; Fan S; Cui M Cell Rep; 2021 Oct; 37(4):109886. PubMed ID: 34706245 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]